Leonard Naymagon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Leonard Naymagon has a total of 89 co-authors. Here are the top co-authors by number of shared publications:
- Douglas Tremblay
Icahn School of Medicine at Mount Sinai, New York, New York, United States
9 shared publications John Mascarenhas
Ichan School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, NY
9 shared publicationsThomas Schiano
Icahn School of Medicine at Mount Sinai, Recanati/Miller Transplantation Institute, New York, NY
9 shared publicationsDouglas Tremblay
Ichan School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, NY
7 shared publications- John Mascarenhas
Icahn School of Medicine at Mount Sinai, New York, New York, United States
7 shared publications Erin Moshier
Department of Population Health Science and Policy, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, United States of America
6 shared publications
Latest Publications
- Open Access
- 11 November 2026
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 10 (12)
Predictors and prognostic impact of spontaneous portal vein thrombosis recanalization in cirrhosis: An individual patient data meta-analysis
Background: Portal vein thrombosis (PVT) in cirrhosis has a quite unpredictable natural history. Spontaneous recanalization may occur, but predictors and prognostic impact remain uncertain. We performed an individual patient data (IPD) meta-analysis to evaluate survival according to spontaneous recanalization and to identify predictors of recanalization. Methods: We included cohort studies of patients with cirrhosis and PVT not receiving anticoagulation and obtained de-identified IPD. All-cause mortality was analyzed using a competing-risk model (competing event: liver transplantation) adjusted for prespecified baseline covariates. Predictors of recanalization were assessed with mixed-effects ordinal logistic regression including a random study intercept. Results: Eight studies contributed 586 patients. Spontaneous recanalization occurred in 264 (47.7%). Overall recanalization was independently associated with lower mortality (aSHR 0.51; 95% CI 0.28–0.90), with the benefit driven by complete recanalization (aSHR 0.45; 95% CI 0.21–0.94). Recanalization of PVT localized in the main portal vein trunk was linked to a strong survival benefit (interaction SHR 0.39; 95% CI 0.16–0.91; p =0.02), whereas no benefit was observed after recanalization of isolated intrahepatic branch thrombosis. PVT recanalization was more likely to occur in Child–Pugh A (aOR 2.63; 95% CI 1.18–5.88), partial thrombosis (aOR 1.69; 95% CI 1.09–2.56), and isolated intrahepatic location (aOR 2.04; 95% CI 1.23–3.33). Conclusions: Spontaneous recanalization occurs in approximately half of patients with cirrhosis and PVT and is associated with improved survival, particularly when complete and involving the main portal vein trunk. These findings underscore its prognostic relevance and indirectly support anticoagulation to promote recanalization.
- 11 November 2026
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 10 (12)
Open AccessPredictors and prognostic impact of spontaneous portal vein thrombosis recanalization in cirrhosis: An individual patient data meta-analysis
Background: Portal vein thrombosis (PVT) in cirrhosis has a quite unpredictable natural history. Spontaneous recanalization may occur, but predictors and prognostic impact remain uncertain. We performed an individual patient data (IPD) meta-analysis to evaluate survival according to spontaneous recanalization and to identify predictors of recanalization. Methods: We included cohort studies of patients with cirrhosis and PVT not receiving anticoagulation and obtained de-identified IPD. All-cause mortality was analyzed using a competing-risk model (competing event: liver transplantation) adjusted for prespecified baseline covariates. Predictors of recanalization were assessed with mixed-effects ordinal logistic regression including a random study intercept. Results: Eight studies contributed 586 patients. Spontaneous recanalization occurred in 264 (47.7%). Overall recanalization was independently associated with lower mortality (aSHR 0.51; 95% CI 0.28–0.90), with the benefit driven by complete recanalization (aSHR 0.45; 95% CI 0.21–0.94). Recanalization of PVT localized in the main portal vein trunk was linked to a strong survival benefit (interaction SHR 0.39; 95% CI 0.16–0.91; p =0.02), whereas no benefit was observed after recanalization of isolated intrahepatic branch thrombosis. PVT recanalization was more likely to occur in Child–Pugh A (aOR 2.63; 95% CI 1.18–5.88), partial thrombosis (aOR 1.69; 95% CI 1.09–2.56), and isolated intrahepatic location (aOR 2.04; 95% CI 1.23–3.33). Conclusions: Spontaneous recanalization occurs in approximately half of patients with cirrhosis and PVT and is associated with improved survival, particularly when complete and involving the main portal vein trunk. These findings underscore its prognostic relevance and indirectly support anticoagulation to promote recanalization.
- Open Access
- 26 April 2025
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 20 (1) , 1-13
Perspectives on the current diagnostic and treatment paradigms in secondary hemophagocytic lymphohistiocytosis (HLH)
Improved awareness of hemophagocytic lymphohistiocytosis (HLH) among clinicians has led to an increase in its diagnosis. Often diagnosis is made based on the HLH- 2004 criteria. While these criteria have considerable strengths, they lack specificity and may be fulfilled in the setting of many pro-inflammatory disorders. Genetic defects affecting cellular cytotoxicity cause familial (primary) HLH. On the other hand, secondary HLH is more a pathophysiologic process common to many conditions, rather than a singular disease entity. Improved genetic, immunologic, and functional testing have changed not only the way we diagnose HLH, but also how we treat it. In 2004, there were few active agents and regimens. In 2024, there are multiple safe and effective targeted therapies. We have begun to understand that routine and immediate use of etoposide-based therapy in secondary HLH is likely not appropriate, and emerging cytokine-directed therapies may be more rational interventions. Moreover, it is recognized that identifying and treating the driver of secondary HLH is at least as important as treating the cytokine storm and immune dysregulation. Unfortunately, over-reliance on, and narrow interpretation of, the HLH- 2004 criteria can lead to overdiagnosis, misdiagnosis, and unneeded exposure to drugs that can be harmful. It is important that clinicians understand the limitations of the current diagnostic paradigms for secondary HLH, and the shortcomings of reflexive use of etoposide-based therapy. Herein we will discuss the pros and cons of the current paradigm for the recognition, diagnosis, and treatment of secondary HLH.
- 26 April 2025
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 20 (1) , 1-13
Open AccessPerspectives on the current diagnostic and treatment paradigms in secondary hemophagocytic lymphohistiocytosis (HLH)
Improved awareness of hemophagocytic lymphohistiocytosis (HLH) among clinicians has led to an increase in its diagnosis. Often diagnosis is made based on the HLH- 2004 criteria. While these criteria have considerable strengths, they lack specificity and may be fulfilled in the setting of many pro-inflammatory disorders. Genetic defects affecting cellular cytotoxicity cause familial (primary) HLH. On the other hand, secondary HLH is more a pathophysiologic process common to many conditions, rather than a singular disease entity. Improved genetic, immunologic, and functional testing have changed not only the way we diagnose HLH, but also how we treat it. In 2004, there were few active agents and regimens. In 2024, there are multiple safe and effective targeted therapies. We have begun to understand that routine and immediate use of etoposide-based therapy in secondary HLH is likely not appropriate, and emerging cytokine-directed therapies may be more rational interventions. Moreover, it is recognized that identifying and treating the driver of secondary HLH is at least as important as treating the cytokine storm and immune dysregulation. Unfortunately, over-reliance on, and narrow interpretation of, the HLH- 2004 criteria can lead to overdiagnosis, misdiagnosis, and unneeded exposure to drugs that can be harmful. It is important that clinicians understand the limitations of the current diagnostic paradigms for secondary HLH, and the shortcomings of reflexive use of etoposide-based therapy. Herein we will discuss the pros and cons of the current paradigm for the recognition, diagnosis, and treatment of secondary HLH.
- 7 March 2024
- Published by Elsevier in Heart, Lung and Circulation
- Vol. 33 (4) , 533-537
The Role of Hereditary Thrombophilia Testing in Management of First-Time Pulmonary Embolism
- 7 March 2024
- Published by Elsevier in Heart, Lung and Circulation
- Vol. 33 (4) , 533-537
The Role of Hereditary Thrombophilia Testing in Management of First-Time Pulmonary Embolism
- Open Access
Splanchnic Vein Thrombosis in Myeloproliferative Neoplasms: Treatment Considerations and Unmet Needs
Patients who develop splanchnic vein thrombosis (SVT) in the setting of a myeloproliferative neoplasm (MPN) are at risk for complications including portal hypertension, bleeding, thrombosis, and death. Prompt multidisciplinary treatment is thus necessary to prevent long-term sequelae. However, optimal management strategies are not well established due to a paucity of data. In this review, we very briefly discuss the epidemiology, pathophysiology, and prognosis of MPN-SVT and then more comprehensively explore treatment considerations of MPN-SVT, including anticoagulation, endovascular/surgical intervention, and cytoreductive therapy. We will also highlight current gaps in our knowledge of MPN-SVT and conclude by suggesting future directions to optimize the treatment of MPN-SVT and improve outcomes.
Open AccessSplanchnic Vein Thrombosis in Myeloproliferative Neoplasms: Treatment Considerations and Unmet Needs
Patients who develop splanchnic vein thrombosis (SVT) in the setting of a myeloproliferative neoplasm (MPN) are at risk for complications including portal hypertension, bleeding, thrombosis, and death. Prompt multidisciplinary treatment is thus necessary to prevent long-term sequelae. However, optimal management strategies are not well established due to a paucity of data. In this review, we very briefly discuss the epidemiology, pathophysiology, and prognosis of MPN-SVT and then more comprehensively explore treatment considerations of MPN-SVT, including anticoagulation, endovascular/surgical intervention, and cytoreductive therapy. We will also highlight current gaps in our knowledge of MPN-SVT and conclude by suggesting future directions to optimize the treatment of MPN-SVT and improve outcomes.
- 10 August 2022
- Published by Springer Nature in International Journal of Hematology
- Vol. 116 (6) , 947-955
Anakinra for the treatment of adult secondary HLH: a retrospective experience
Anti-cytokine therapies have been gaining attention as a means of improving outcomes in adult secondary HLH (asHLH), which currently has poor outcomes when treated with standard etoposide-based therapies. Anakinra is an interleukin-1 antagonist that is increasingly being used in the management of asHLH. Here is described a multi-hospital series of 16 adult patients with secondary HLH treated with anakinra. Provoking factors of secondary HLH included hematologic malignancy (n = 7, 44%), bacterial infection (n = 7, 44%), viral infection (n = 5, 31%), rheumatologic disorder (n = 4, 25%), and unknown (n = 1, 6%). Five patients remained alive at time of last follow-up (OS = 31%). Median OS was 1.7 months from initiation of anakinra (range 0.2–59). OS among patients with rheumatologic causes of secondary HLH was 75%, whereas only 17% of patients with other provoking factors survived (p = 0.0293). Anakinra was well tolerated, with only 1 patient experiencing associated toxicity (grade 3 liver injury). Anakinra may be useful in the management of asHLH provoked by rheumatologic conditions, although its benefit in asHLH provoked by other factors may be limited.
- 10 August 2022
- Published by Springer Nature in International Journal of Hematology
- Vol. 116 (6) , 947-955
Anakinra for the treatment of adult secondary HLH: a retrospective experience
Anti-cytokine therapies have been gaining attention as a means of improving outcomes in adult secondary HLH (asHLH), which currently has poor outcomes when treated with standard etoposide-based therapies. Anakinra is an interleukin-1 antagonist that is increasingly being used in the management of asHLH. Here is described a multi-hospital series of 16 adult patients with secondary HLH treated with anakinra. Provoking factors of secondary HLH included hematologic malignancy (n = 7, 44%), bacterial infection (n = 7, 44%), viral infection (n = 5, 31%), rheumatologic disorder (n = 4, 25%), and unknown (n = 1, 6%). Five patients remained alive at time of last follow-up (OS = 31%). Median OS was 1.7 months from initiation of anakinra (range 0.2–59). OS among patients with rheumatologic causes of secondary HLH was 75%, whereas only 17% of patients with other provoking factors survived (p = 0.0293). Anakinra was well tolerated, with only 1 patient experiencing associated toxicity (grade 3 liver injury). Anakinra may be useful in the management of asHLH provoked by rheumatologic conditions, although its benefit in asHLH provoked by other factors may be limited.
- 5 April 2022
- Published by Wiley in European Journal of Haematology
- Vol. 109 (1) , 69-74
Direct oral anticoagulants versus warfarin in patients with single antibody‐positive anti‐phospholipid syndrome
Background: The role of direct oral anticoagulants (DOACs) among patients with antiphospholipid syndrome (APLS) remains unclear. Warfarin has been shown to be superior to DOACs among high‐risk APLS patients (particularly those with triple‐positive APLS). However, it remains unknown whether DOACs may be appropriate for lower‐risk patients such as those with single‐positive APLS.Methods: We conducted a retrospective study comparing the risk of recurrent thrombosis among single‐positive APLS patients treated with DOACs (apixaban or rivaroxaban), and those treated with warfarin.Results: One‐hundred‐forty‐three single‐positive APLS patients, newly started on anticoagulation following a first thrombotic event, were included. Median follow‐up was 54 months (IQR 29–73 months). Ninety‐one patients (64%) received warfarin and 52 patients (36%) received a DOAC. Six patients (6.6%) who received warfarin experienced a recurrent thrombotic event compared with 3 of 52 (5.8%) patients who received a DOAC (p = .845). There was no difference in event‐free survival between groups (HR DOAC:Warfarin = 0.952, 95% CI 0.232 – 3.908). Major bleeding was similar in both groups.Conclusions: These findings suggest that DOACs may be a safe and effective option for patients with single‐positive APLS. Prospective studies are needed to confirm these findings.
- 5 April 2022
- Published by Wiley in European Journal of Haematology
- Vol. 109 (1) , 69-74
Direct oral anticoagulants versus warfarin in patients with single antibody‐positive anti‐phospholipid syndrome
Background: The role of direct oral anticoagulants (DOACs) among patients with antiphospholipid syndrome (APLS) remains unclear. Warfarin has been shown to be superior to DOACs among high‐risk APLS patients (particularly those with triple‐positive APLS). However, it remains unknown whether DOACs may be appropriate for lower‐risk patients such as those with single‐positive APLS.Methods: We conducted a retrospective study comparing the risk of recurrent thrombosis among single‐positive APLS patients treated with DOACs (apixaban or rivaroxaban), and those treated with warfarin.Results: One‐hundred‐forty‐three single‐positive APLS patients, newly started on anticoagulation following a first thrombotic event, were included. Median follow‐up was 54 months (IQR 29–73 months). Ninety‐one patients (64%) received warfarin and 52 patients (36%) received a DOAC. Six patients (6.6%) who received warfarin experienced a recurrent thrombotic event compared with 3 of 52 (5.8%) patients who received a DOAC (p = .845). There was no difference in event‐free survival between groups (HR DOAC:Warfarin = 0.952, 95% CI 0.232 – 3.908). Major bleeding was similar in both groups.Conclusions: These findings suggest that DOACs may be a safe and effective option for patients with single‐positive APLS. Prospective studies are needed to confirm these findings.
- 26 March 2022
- Published by Elsevier in Journal of Vascular Surgery: Venous and Lymphatic Disorders
- Vol. 10 (4) , 841-845
Utility of hereditary thrombophilia testing among patients with lower extremity deep vein thrombosis
- 26 March 2022
- Published by Elsevier in Journal of Vascular Surgery: Venous and Lymphatic Disorders
- Vol. 10 (4) , 841-845
Utility of hereditary thrombophilia testing among patients with lower extremity deep vein thrombosis
- 8 November 2021
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 44 (2) , 393-398
The utility of hereditary thrombophilia testing among patients with unprovoked venous thromboembolism
Introduction: Hereditary‐thrombophilia (HT) testing is often sent during the evaluation of patients with unprovoked venous thromboembolism (VTE). This remains a frequent practice even though the results of such testing are often of unclear practical significance.Methods: We conducted a multicenter retrospective study to assess whether HT is associated with risk of recurrent VTE among patients who discontinue anticoagulation (AC) following an unprovoked VTE.Results: A total of 528 adult patients were included, 28% of whom (N = 110) tested positive for HT. Median follow‐up was 55 months (IQR 40‐66 months) following AC discontinuation. One hundred and twenty‐four patients (23%) had a recurrent VTE during follow‐up, including 29/110 with HT (26%) and 95/418 without HT (23%). Risk of recurrent VTE over time was similar between the two groups (logrank P = .47). The HR for recurrence among patients with HT was 1.17 (95% CI 0.76 to 1.81). On multivariable analysis, HT was not associated with recurrence of VTE (HR with HT = 1.07 (95% CI 0.69‐1.65), P = .74). The only factor significantly associated with risk of VTE recurrence on multivariable analysis was presence of PE (as opposed to DVT alone) (HR = 1.54, 95% CI 1.02‐2.30, P = .035).Conclusion: The presence of HT was not associated with risk of recurrent VTE in this cohort of patients. These findings underscore the questionable clinical utility of routine thrombophilia testing among patient with unprovoked VTE and suggest that such testing should not be routinely pursued.
- 8 November 2021
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 44 (2) , 393-398
The utility of hereditary thrombophilia testing among patients with unprovoked venous thromboembolism
Introduction: Hereditary‐thrombophilia (HT) testing is often sent during the evaluation of patients with unprovoked venous thromboembolism (VTE). This remains a frequent practice even though the results of such testing are often of unclear practical significance.Methods: We conducted a multicenter retrospective study to assess whether HT is associated with risk of recurrent VTE among patients who discontinue anticoagulation (AC) following an unprovoked VTE.Results: A total of 528 adult patients were included, 28% of whom (N = 110) tested positive for HT. Median follow‐up was 55 months (IQR 40‐66 months) following AC discontinuation. One hundred and twenty‐four patients (23%) had a recurrent VTE during follow‐up, including 29/110 with HT (26%) and 95/418 without HT (23%). Risk of recurrent VTE over time was similar between the two groups (logrank P = .47). The HR for recurrence among patients with HT was 1.17 (95% CI 0.76 to 1.81). On multivariable analysis, HT was not associated with recurrence of VTE (HR with HT = 1.07 (95% CI 0.69‐1.65), P = .74). The only factor significantly associated with risk of VTE recurrence on multivariable analysis was presence of PE (as opposed to DVT alone) (HR = 1.54, 95% CI 1.02‐2.30, P = .035).Conclusion: The presence of HT was not associated with risk of recurrent VTE in this cohort of patients. These findings underscore the questionable clinical utility of routine thrombophilia testing among patient with unprovoked VTE and suggest that such testing should not be routinely pursued.
- Open Access
- 1 February 2021
- Published by Elsevier in Pathology - Research and Practice
- Vol. 218, 153321
Can we truly diagnose adult secondary hemophagocytic lymphohistiocytosis (HLH)? A critical review of current paradigms
- 1 February 2021
- Published by Elsevier in Pathology - Research and Practice
- Vol. 218, 153321
Open AccessCan we truly diagnose adult secondary hemophagocytic lymphohistiocytosis (HLH)? A critical review of current paradigms